{"id":794692,"date":"2024-12-12T16:21:11","date_gmt":"2024-12-12T21:21:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/"},"modified":"2024-12-12T16:21:11","modified_gmt":"2024-12-12T21:21:11","slug":"portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/","title":{"rendered":"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <em>No impact at this time on the listing of the Company\u2019s Ordinary Shares on Nasdaq<\/em>\n        <\/li>\n<li style=\"text-align:justify\">\n          <em>Company intends to submit to Nasdaq a compliance plan<\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">WESTPORT, Conn., Dec.  12, 2024  (GLOBE NEWSWIRE) &#8212; Portage Biotech Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, announced today that it received written notice (the \u201cNotice\u201d) from The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) on December 10, 2024 indicating that the Company was not in compliance with the minimum shareholders\u2019 equity requirement for continued listing on The Nasdaq Capital Market (the \u201cCapital Market\u201d) as set forth in Nasdaq Listing Rule 5550(b)(1) (the \u201cShareholders\u2019 Equity Requirement\u201d), because the Company\u2019s shareholders\u2019 equity of $695,000 as of September 30, 2024, as reported in the Company\u2019s Report on Form 6-K containing unaudited condensed consolidated interim financial statements for the three and six months ended September 30, 2024, filed with the United States Securities and Exchange Commission (the \u201cSEC\u201d) on November 26, 2024, was below the required minimum of $2.5 million, and because, as of the date of the Notice (and as of the date of this press release), the Company did not meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income from continuing operations of at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. The Notice has no effect at this time on the listing of the Company\u2019s ordinary shares (the \u201cOrdinary Shares\u201d), which continue to trade on the Capital Market under the symbol \u201cPRTG\u201d.<\/p>\n<p align=\"justify\">As indicated in the Notice, the Company has a period of 45 calendar days from the date of the Notice, or until January 24, 2025, to submit to Nasdaq a plan to regain compliance with the Shareholders\u2019 Equity Requirement or achieve compliance with an alternative continued listing standard for the Capital Market (the \u201cCompliance Plan\u201d). If Nasdaq accepts the Compliance Plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notice, or until June 8, 2025, to evidence compliance. If Nasdaq does not accept the Compliance Plan, then Nasdaq will provide written notice to the Company that the Ordinary Shares will be subject to delisting. At such time, the Company may appeal the delisting determination to a Nasdaq hearings panel.<\/p>\n<p align=\"justify\">The Company intends to submit a Compliance Plan by the January 24, 2025 deadline. There can be no assurance that the Company will be able to regain compliance with the Shareholders\u2019 Equity Requirement, achieve compliance with an alternative continued listing standard for the Capital Market or maintain compliance with any other listing requirements under the Nasdaq Listing Rules.<\/p>\n<p align=\"justify\">\n        <strong>About Portage Biotech Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Portage is a clinical-stage immuno-oncology company with a portfolio of multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. The Company has made the decision to discontinue its sponsored trial for its the invariant natural killer T-cell (iNKT) program and pause further patient accrual to its sponsored adenosine trial program (ADPORT-601 trial) for its potentially best-in-class adenosine antagonists PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor). The Company is exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a company wind down, further financing efforts or other strategic actions. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GE29h0k5grqLQMEwuaFDCfA_7NVrLQMqDODem6takP731gi8bcLo7Tz0tTOmUQqzqVFjHeEATvq9kViQEY7mTsUCgPEFkyFSkac4WCwwGkE=\" rel=\"nofollow\" target=\"_blank\">www.portagebiotech.com<\/a> or find us on LinkedIn at Portage Biotech Inc.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements, including, but not limited to, statements regarding the Company\u2019s ability to regain compliance with the Shareholders\u2019 Equity Requirement, achieve compliance with an alternative continued listing standard for the Capital Market or maintain compliance with any other listing requirements under the Nasdaq Listing Rules, the Company\u2019s intentions to submit a Compliance Plan by the deadline, and the Company\u2019s intention to take actions to regain compliance with the Shareholders\u2019 Equity Requirement or achieve compliance with an alternative continued listing standard for the Capital Market. The Company\u2019s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company may not meet the Shareholders\u2019 Equity Requirement during any compliance period or in the future, the risk that the Company may not otherwise meet the requirements for continued listing for the Capital Market or maintain compliance with any other listing requirements under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, and other factors set forth in \u201cItem 3 \u2013 Key Information \u2013 Risk Factors\u201d in the Company\u2019s Annual Report on Form 20-F for the year ended March 31, 2024, filed with the SEC on August 14, 2024, and \u201cBusiness Environment \u2013 Risk Factors\u201d in the Company\u2019s Management\u2019s Discussion and Analysis for the Three and Six Months ended September 30, 2024 filed as Exhibit 99.2 to the Company\u2019s Form 6-K, filed with the SEC on November 26, 2024. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.<\/p>\n<p align=\"justify\">FOR MORE INFORMATION, PLEASE CONTACT:<\/p>\n<p align=\"justify\">Investor Relations:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ea8U_ieEqdajzfquFb9kvMFlP61ID0ya3uqzC_xhIOQvXXHcLk4TNoFQMJ6ewptZvpJKxxsVWdmcH7Q63_d5aPnwQ8h1XYKj6hmSeLZ6WMyXNQohP3JeH4yh5CNdWfDHMJ2YJ_8kM7LRkAIvX0hKxUu95BHQnhQsgiqATl531xZZY8a75kPRkjQqIET-86T7fi6oLuL4oeIhCTRWdFpWIwXPHZOtm1LrIZekOBY6rOkVDn0Yh05Z5ayMfUKeaDUSSGOeJDexSqPG92tuGPV6rw==\" rel=\"nofollow\" target=\"_blank\">ir@portagebiotech.com<\/a><\/p>\n<p align=\"justify\">Media Relations:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xmiv9O9yB-4S6hck-DIoEqm2Nmdey24fEpIJxOaO9c0XYnFvhyx9BrX-E339ohnmLU6SaaknFa5QGPbClyjHwmqTyENDpuS6rbBlnjG5zxcfPeGZ890IqCZVPpu5MbZ_erWsejrdfE7RcXw5awd6faaVRhh_Lzkffo6Gu3GFNK7-XIYyIsfaQb8ANUhQt9mlEjHar24Kt2Cv405ZZVG_WtaYvH6c4jKJ3ooHmpsWHjV84MdriXCQZZdxCn2_o_BeXB0PsC2nWERyDZnZDKV-ZQ==\" rel=\"nofollow\" target=\"_blank\">media@portagebiotech.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2JkZDdkZmMtYTdmNS00M2ZmLTg2MGEtYjM5ZmEyNDdkMmQ0LTEyMjEzMjI=\/tiny\/Portage-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>No impact at this time on the listing of the Company\u2019s Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; Portage Biotech Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, announced today that it received written notice (the \u201cNotice\u201d) from The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) on December 10, 2024 indicating that the Company was not in compliance with the minimum shareholders\u2019 equity requirement for continued listing on The Nasdaq Capital Market (the \u201cCapital Market\u201d) as set forth in Nasdaq Listing Rule 5550(b)(1) (the \u201cShareholders\u2019 Equity Requirement\u201d), because the Company\u2019s shareholders\u2019 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-794692","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"No impact at this time on the listing of the Company\u2019s Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; Portage Biotech Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, announced today that it received written notice (the \u201cNotice\u201d) from The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) on December 10, 2024 indicating that the Company was not in compliance with the minimum shareholders\u2019 equity requirement for continued listing on The Nasdaq Capital Market (the \u201cCapital Market\u201d) as set forth in Nasdaq Listing Rule 5550(b)(1) (the \u201cShareholders\u2019 Equity Requirement\u201d), because the Company\u2019s shareholders\u2019 &hellip; Continue reading &quot;Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-12T21:21:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter\",\"datePublished\":\"2024-12-12T21:21:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/\"},\"wordCount\":953,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/\",\"name\":\"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=\",\"datePublished\":\"2024-12-12T21:21:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/","og_locale":"en_US","og_type":"article","og_title":"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter - Market Newsdesk","og_description":"No impact at this time on the listing of the Company\u2019s Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) &#8212; Portage Biotech Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, announced today that it received written notice (the \u201cNotice\u201d) from The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) on December 10, 2024 indicating that the Company was not in compliance with the minimum shareholders\u2019 equity requirement for continued listing on The Nasdaq Capital Market (the \u201cCapital Market\u201d) as set forth in Nasdaq Listing Rule 5550(b)(1) (the \u201cShareholders\u2019 Equity Requirement\u201d), because the Company\u2019s shareholders\u2019 &hellip; Continue reading \"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-12T21:21:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter","datePublished":"2024-12-12T21:21:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/"},"wordCount":953,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/","name":"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=","datePublished":"2024-12-12T21:21:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxODY4MCM2NjM1NzkxIzIyMDk3Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-announces-receipt-of-nasdaq-noncompliance-letter\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=794692"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794692\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=794692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=794692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=794692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}